P. Shattock

发表

How could a Gluten- and casein-Free Diet Ameliorate symptoms Associated with Autism spectrum conditions?

P. Whiteley, P. Shattock, Kevin Carr, 2010 .

Role of neuropeptides in autism and their relationships with classical neurotransmitters

T. Berney, F. Rowell, P. Shattock, 1990 .

‘Opioid peptides and dipeptidyl peptidase in autism’

R. Waring, P. Shattock, M. Hooper, 2004, Developmental medicine and child neurology.

Spot urinary creatinine excretion in pervasive developmental disorders

P. Whiteley, K. Dodou, R. Waring, 2006, Pediatrics international : official journal of the Japan Pediatric Society.

Correlates of Overlapping Fatigue Syndromes

P. Whiteley, P. Shattock, Lynda Todd, 2004 .

Indolyl-3-acryloylglycine (IAG) is a putative diagnostic urinary marker for autism spectrum disorders.

P. Whiteley, P. Groundwater, P. Shattock, 2003, Medical science monitor : international medical journal of experimental and clinical research.

A Gluten-Free Diet as an Intervention for Autism and Associated Spectrum Disorders: Preliminary Findings

P. Whiteley, P. Shattock, J. Rodgers, 1999 .

NDT_A_221901 2885..2891

P. Whiteley, P. Shattock, Kevin Carr, 2019 .

The Use of Medication for People with Autism Spectrum Disorders

P. Whiteley, P. Shattock, 2006 .

Bridging the Gap Between Physical Health and Autism Spectrum Disorder

P. Whiteley, L. Amet, P. Shattock, 2020, Neuropsychiatric disease and treatment.

Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders: Behavioural and psychometric measures of dietary response

P. Whiteley, P. Shattock, K. Kvist, 2014, Nutritional neuroscience.

Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention

P. Whiteley, P. Shattock, Paul Whiteley, 2002, Expert opinion on therapeutic targets.

Gluten- and casein-free dietary intervention for autism spectrum conditions

P. Whiteley, K. Reichelt, P. Shattock, 2012, Front. Hum. Neurosci..

Urinary compounds in autism.

T. Berney, P. Shattock, K. Bretherton, 2004, Journal of intellectual disability research : JIDR.

Feeding Patterns in Autism

P. Whiteley, P. Shattock, J. Rodgers, 2000 .

Body mass index of children from the United Kingdom diagnosed with pervasive developmental disorders

P. Whiteley, K. Dodou, P. Shattock, 2004, Pediatrics international : official journal of the Japan Pediatric Society.

Rapid analysis of low levels of indolyl-3-acryloylglycine in human urine by high-performance liquid chromatography.

P. Shattock, D. Savery, M. Mills, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Proteins, peptides and autism. II: Implications for the education and care of people with autism

G. Lowdon, P. Shattock, 1991 .

The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders

P. Whiteley, K. Reichelt, P. Shattock, 2010, Nutritional neuroscience.

Is Autism Inborn And Lifelong For Everyone?

P. Whiteley, P. Shattock, Kevin Carr, 2019, Neuropsychiatric disease and treatment.

Research, Clinical, and Sociological Aspects of Autism

P. Whiteley, P. Shattock, Kevin Carr, 2021, Frontiers in Psychiatry.

Development and reproducibility of a novel high-performance liquid-chromatography monolithic column method for the detection and quantification of trans-indolyl-3-acryloylglycine in human urine.

P. Whiteley, P. Shattock, Kevin Carr, 2009, Biomedical chromatography : BMC.

Trends in Developmental, Behavioral and somatic Factors by Diagnostic sub-group in pervasive Developmental Disorders: A Follow-up Analysis

K. Dodou, P. Shattock, Lynda Todd, 2009 .

Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay

P. Whiteley, K. Dodou, S. Wilkinson, 2015, Pharmaceutical development and technology.

MMR and Autism: C. Gillberg & H. Heijdal, Autism, 1998, 2(4), 423-4

P. Whiteley, P. Shattock, Paul Whiteley, 1999 .

Clinical Features Associated with Autism

P. Whiteley, P. Shattock, J. Rodgers, 1998 .

Autistic Disorder in Nineteenth-century London

P. Shattock, M. Waltz, 2004, Autism : the international journal of research and practice.

Identification of indolyl‐3‐acryloylglycine in the urine of people with autism

Rosaleen J. Anderson, W. J. Lough, P. Groundwater, 2002, The Journal of pharmacy and pharmacology.

NDT_A_221901 2885..2891

P. Whiteley, P. Shattock, Kevin Carr, 2019 .

Development and reproducibility of a novel high-performance liquid-chromatography monolithic column method for the detection and quantification of trans-indolyl-3-acryloylglycine in human urine.

P. Whiteley, P. Shattock, Kevin Carr, 2009, Biomedical chromotography.